Mark Elliott Boulding Sells 15,312 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 15,312 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $44.74, for a total value of $685,058.88. Following the completion of the sale, the vice president now owns 32,805 shares of the company’s stock, valued at $1,467,695.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Mark Elliott Boulding also recently made the following trade(s):

  • On Friday, June 28th, Mark Elliott Boulding sold 77,575 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.00, for a total value of $3,490,875.00.
  • On Monday, July 1st, Mark Elliott Boulding sold 181,667 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.00, for a total value of $8,175,015.00.

PTCT opened at $43.96 on Thursday. The firm has a market capitalization of $2.58 billion, a P/E ratio of -23.89 and a beta of 1.76. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.35 and a quick ratio of 3.24. PTC Therapeutics, Inc. has a 1-year low of $27.53 and a 1-year high of $48.99. The business has a 50 day moving average price of $42.01.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.55). The firm had revenue of $53.58 million during the quarter, compared to analyst estimates of $70.38 million. PTC Therapeutics had a negative return on equity of 32.42% and a negative net margin of 68.99%. The business’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.46) earnings per share. As a group, research analysts predict that PTC Therapeutics, Inc. will post -2.54 earnings per share for the current fiscal year.

PTCT has been the subject of a number of research analyst reports. Bank of America upgraded Copa from a “neutral” rating to a “buy” rating in a research report on Monday, May 13th. ValuEngine upgraded United Overseas Bank from a “sell” rating to a “hold” rating in a research report on Monday, June 17th. Citigroup set a $47.00 target price on Quanta Services and gave the stock a “buy” rating in a research report on Friday, May 3rd. Sanford C. Bernstein set a €12.10 ($14.07) target price on Metro and gave the stock a “sell” rating in a research report on Thursday, April 11th. Finally, Cowen restated a “buy” rating and issued a $149.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, May 8th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. PTC Therapeutics currently has an average rating of “Buy” and an average price target of $50.56.

Several hedge funds and other institutional investors have recently bought and sold shares of PTCT. Metropolitan Life Insurance Co NY boosted its holdings in PTC Therapeutics by 8.7% in the first quarter. Metropolitan Life Insurance Co NY now owns 16,510 shares of the biopharmaceutical company’s stock worth $621,000 after purchasing an additional 1,327 shares in the last quarter. MetLife Investment Advisors LLC boosted its holdings in PTC Therapeutics by 8.7% in the first quarter. MetLife Investment Advisors LLC now owns 22,877 shares of the biopharmaceutical company’s stock worth $861,000 after purchasing an additional 1,827 shares in the last quarter. Marshall Wace North America L.P. boosted its holdings in PTC Therapeutics by 79.5% in the first quarter. Marshall Wace North America L.P. now owns 662,587 shares of the biopharmaceutical company’s stock worth $24,940,000 after purchasing an additional 293,495 shares in the last quarter. Sector Gamma AS bought a new stake in PTC Therapeutics in the first quarter worth $7,330,000. Finally, Botty Investors LLC bought a new stake in PTC Therapeutics in the first quarter worth $75,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.

Read More: Why are percentage decliners important?

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.